Literature DB >> 22882525

Prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome.

John W Warren1, Daniel J Clauw, Patricia Langenberg.   

Abstract

UNLABELLED: Study Type - Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Interstitial cystitis/painful bladder syndrome (IC/PBS) comprises pain perceived to be from the bladder, urinary urgency and frequency, and nocturia. As diagnosed at present, it is primarily identified in adult women. It is a chronic disease yet its natural history has not been well studied. In a prospective study of 304 incident female IC/PBS cases followed for a median of 33 months after onset, women with baseline chronic fatigue syndrome had a worse prognosis for IC/PBS. Mild IC/PBS at baseline was the only variable that was directly associated with a good prognosis.
OBJECTIVE: To identify baseline variables that predict the prognosis of interstitial cystitis/painful bladder syndrome (IC/PBS) in women seeking medical care for recent onset of this syndrome. SUBJECTS AND METHODS: In a prospective study of women with incident IC/PBS (≤12 months of symptoms), we contacted patients at intervals and asked standardized questions about IC/PBS symptoms in the previous week. Logistic regression analyses assessed baseline variables as predictors of mild vs more severe IC/PBS at the last follow-up.
RESULTS: Median length of follow-up was 33 months after onset of IC/PBS; 304 (97%) patients had at least one follow-up assessment. Mild IC/PBS at baseline was the only variable that was directly associated with a mild IC/PBS endpoint. Conversely, a history of chronic fatigue syndrome (CFS) was inversely associated with a mild endpoint of IC/PBS (i.e. individuals with CFS had a worse prognosis for their IC/PBS symptoms).
CONCLUSIONS: At a median of nearly 3 years after onset, baseline mild IC/PBS was directly associated with a milder disease severity. Baseline co-morbid CFS was associated with more severe disease. Whether CFS was uniquely associated or represented several co-morbid non-bladder syndromes (NBSs) could not be determined.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 22882525     DOI: 10.1111/j.1464-410X.2012.11422.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Clinical and Psychosocial Predictors of Urological Chronic Pelvic Pain Symptom Change in 1 Year: A Prospective Study from the MAPP Research Network.

Authors:  Bruce D Naliboff; Alisa J Stephens; H Henry Lai; James W Griffith; J Quentin Clemens; Susan Lutgendorf; Larissa V Rodriguez; Craig Newcomb; Siobhan Sutcliffe; Wensheng Guo; John W Kusek; J Richard Landis
Journal:  J Urol       Date:  2017-05-18       Impact factor: 7.450

2.  Symptom Duration in Patients With Urologic Chronic Pelvic Pain Syndrome is not Associated With Pain Severity, Nonurologic Syndromes and Mental Health Symptoms: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Network Study.

Authors:  Larissa V Rodríguez; Alisa J Stephens; J Quentin Clemens; Dedra Buchwald; Claire Yang; Henry H Lai; John N Krieger; Craig Newcomb; Cate S Bradley; Bruce Naliboff
Journal:  Urology       Date:  2018-11-16       Impact factor: 2.649

3.  Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-05-13       Impact factor: 5.820

4.  Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-06-30       Impact factor: 5.820

Review 5.  Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder.

Authors:  Chris Mullins; Tamara Bavendam; Ziya Kirkali; John W Kusek
Journal:  Transl Androl Urol       Date:  2015-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.